Measuring Health-Related Quality Of Life (HRQoL) In Leukemia Patients

Published Dec 17, 2012
Chicago, IL, USA – Researchers at Northwestern University have developed a new questionnaire to measure the quality of life (QoL) issues associated with leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu). This questionnaire joins a large family of similar questionnaires targeted to various malignancies and other chronic conditions, the Functional Assessment of Chronic Illness Therapy (see www.facit.org). The FACT-Leu is a brief, valid measure of general and leukemia-specific symptoms and concerns associated with leukemia and its treatment. Prior to the development of the FACT-Leu, options for measuring leukemia-specific QoL in clinical trials or practice were limited.  Working with an international team of investigators and patients to ensure cross-cultural applicability of the questionnaire, lead author David Cella, Ph.D., and his team developed and validated the FACT-Leu to measure the QoL of patients with acute and chronic leukemia. According to Cella, “Understanding the impact of leukemia and its treatments has never been more important, with an emerging array of treatment options and schedules that patients must consider and endure. By considering patient concerns such as the severity of symptoms and/or treatment effects, family burden, life disruption and disability, clinicians and researchers are better able to understand the broader implications of the disease and its impact on patients and their families.” The study, "Measuring Health-Related Quality of Life in Leukemia: The Functional Assessment of Cancer Therapy – Leukemia (FACT-Leu) Questionnaire," is published in Value in Health, the official journal of the International Society for Pharmacoeconomics and Outcomes Research (ISPOR).

Value in Health (ISSN 1098-3015) publishes papers, concepts, and ideas that advance the field of pharmacoeconomics and outcomes research as well as policy papers to help health care leaders make evidence-based decisions. The journal is published bi-monthly and has over 8,000 subscribers (clinicians, decision makers, and researchers worldwide).

International Society for Pharmacoeconomics and Outcomes Research (ISPOR) is a nonprofit, international, educational and scientific organization that strives to increase the efficiency, effectiveness, and fairness of health care resource use to improve health.

For more information: www.ispor.org

Related Stories

The Ozempic Paradox: How Spending Billions on Weight-Loss Drug Would Actually Reduce Overall Medicare Costs

Oct 14, 2025

Value in Health, the official journal of ISPOR—The Professional Society for Health Economics and Outcomes Research, announced today the publication of a landmark study by researchers at the University of Washington, Curta, Inc, and the University of North Carolina showing that broad Medicare coverage of semaglutide in diabetes, obesity, and liver disease could generate significant cost savings while delivering substantial health benefits to beneficiaries. The report, “Comprehensive Access to Semaglutide: Clinical and Economic Implications for Medicare,” was published in the October 2025 issue of Value in Health.

ISPOR Launches New Content on Whole Health

Sep 23, 2025

ISPOR announced that it has launched new website content on whole health, a topic of increasing importance as health systems across the globe grapple with providing the best possible healthcare to patients within constrained budgets.
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×